(Q46787046)

25 December 2017

title

Lipid A and liposomes containing lipid A as antigens and adjuvants (English)

1 reference

25 December 2017

author name string

Carl R Alving

series ordinal

1

1 reference

25 December 2017

Mangala Rao

series ordinal

2

1 reference

25 December 2017

language of work or name

English

0 references

publication date

26 December 2007

1 reference

25 December 2017

published in

Vaccine

1 reference

25 December 2017

volume

26

1 reference

25 December 2017

issue

24

1 reference

25 December 2017

page(s)

3036-3045

1 reference

25 December 2017

Structure of bacterial lipopolysaccharides

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.002

Lipid A fractions analyzed by a technique involving thin-layer chromatography and enzyme-linked immunosorbent assay.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.002

Heterogeneity of lipid A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.002

Endotoxins: relationships between structure, function, and activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.002

Biological Activities of Chemically Modified Endotoxins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.002

Structural requirements of lipid A for endotoxicity and other biological activities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.002

Antibodies to liposomal phosphatidylserine and phosphatidic acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.002

Antibodies to liposomal phosphatidylcholine and phosphatidylsulfocholine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.002

Induction and detection of antibodies to squalene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.002

Membrane lipid composition modulates the binding specificity of a monoclonal antibody against liposomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.002

Antibodies to liposomes, phospholipids and phosphate esters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.002

Phosphate-binding specificities of monoclonal antibodies against phosphoinositides in liposomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.002

ATP specifically bound as a hapten to a monoclonal anti-phospholipid antibody retains phosphate donor activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.002

Cross-reactions of nucleic acids with monoclonal antibodies to phosphatidylinositol phosphate and cholesterol.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.002

Antibodies to cholesterol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.002

Innate immunity: an overview

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.002

LPS, TLR4 and infectious disease diversity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.002

Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.002

Human MD-2 discrimination of meningococcal lipid A structures and activation of TLR4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.002

Kdo2-Lipid A of Escherichia coli, a defined endotoxin that activates macrophages via TLR-4.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.002

Control of B-cell responses by Toll-like receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.002

Synthetic vaccines: the role of adjuvants in immune targeting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.002

Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.002

Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.002

Immunology. Mouse studies question importance of toll-like receptors to vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.002

Immunology: Toll-like receptors and antibody responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.002

Toll-like receptors and antibody responses (Reply)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.002

The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.002

Does endotoxin stimulate cells by mimicking ceramide?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.002

Self-reactive antibodies (natural autoantibodies) in healthy individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.002

CD5+ B lymphocytes, polyreactive antibodies and the human B-cell repertoire

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.002

The molecular basis for a polyspecific antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.002

Polyreactive antigen-binding B (PAB-) cells are widely distributed and the PAB population consists of both B-1+ and B-1- phenotypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.002

Polyreactivity of antibody molecules

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.002

Large numbers of cells in normal mice produce antibody components of isologous erythrocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.002

Phosphatidyl choline is recognized by a series of Ly-1+ murine B cell lymphomas specific for erythrocyte membranes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.002

Normal mouse peritoneum contains a large population of Ly-1+ (CD5) B cells that recognize phosphatidyl choline. Relationship to cells that secrete hemolytic antibody specific for autologous erythrocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.002

Restricted immunoglobulin variable region gene usage by normal Ly-1 (CD5+) B cells that recognize phosphatidyl choline

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.002

Antiphospholipid Antibodies Reactive with Bromelain-Treated Mouse Erythrocytes in Mice, Rats and Rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.002

Characterization of anti-phosphatidylcholine polyreactive natural autoantibodies from normal human subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.002

Antibodies to phospholipids and liposomes: binding of antibodies to cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.002

Antibodies to lipids and liposomes: immunology and safety.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.002

Naturally occurring antibodies to cholesterol: a new theory of LDL cholesterol metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.002

Anticardiolipin response in acute infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.002

Preparation and properties of antisera against the lipid-A component of bacterial lipopolysaccharides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.002

Detection and Specificity of Lipid A Antibodies Using Liposomes Sensitized with Lipid A and Bacterial Lipopolysaccharides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.002

Production and characterization of monoclonal antibodies that bind to phosphatidylinositol 4,5-bisphosphate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.002

Production of oligosaccharide-binding monoclonal antibodies of diverse specificities by immunization with purified tumor-associated glycolipids inserted into liposomes with lipid A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.002

Immunogenicity of liposomal malaria sporozoite antigen in monkeys: adjuvant effects of aluminium hydroxide and non-pyrogenic liposomal lipid A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.002

Lipopolysaccharide, lipid A, and liposomes containing lipid A as immunologic adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.002

Phase-I study of intravenous modified lipid A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.002

Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.002

Safety, immunogenicity, and efficacy of Plasmodium falciparum repeatless circumsporozoite protein vaccine encapsulated in liposomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.002

Immunogenicity and antitumor activity of a liposomal MUC1 peptide-based vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.002

Selection of potent immunological adjuvants for vaccine construction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.002

Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.002

Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.002

Potent enhancement of cellular and humoral immune responses against recombinant hepatitis B antigens using AS02A adjuvant in healthy adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.002

New hepatitis B vaccine formulated with an improved adjuvant system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.002

7 January 2021

HIV vaccines 1983-2003.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.002

Progress towards the development of a HIV-1 gp41-directed vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.002

HIV-1, lipid rafts, and antibodies to liposomes: implications for anti-viral-neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.002

HIV vaccine design and the neutralizing antibody problem

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.002

Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.002

Specific phospholipid recognition by human immunodeficiency virus type-1 neutralizing anti-gp41 2F5 antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.002

Difficulties in eliciting broadly neutralizing anti-HIV antibodies are not explained by cardiolipin autoreactivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.002

Reassessment of autoreactivity of the broadly neutralizing HIV antibodies 4E10 and 2F5 and retrospective analysis of clinical safety data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.002

4E10 and 2F5 monoclonal antibodies: binding specificities to phospholipids, tolerance, and clinical safety issues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.002

Monoclonal antibodies to phosphatidylinositol phosphate neutralize human immunodeficiency virus type 1: role of phosphate-binding subsites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.002

Calcium modulation of monoclonal antibody binding to phosphatidylinositol phosphate.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.002

Stimulation of the ceramide pathway partially mimics lipopolysaccharide-induced responses in murine peritoneal macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.002

inferred from DOI database lookup

7 January 2021

based on heuristic

Toxicity and immunogenicity of Neisseria meningitidis lipopolysaccharide incorporated into liposomes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.002

inferred from DOI database lookup

7 January 2021

based on heuristic

Altered in vivo activity of liposome-incorporated lipopolysaccharide and lipid A.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.002

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2007.12.002

1 reference

25 December 2017

1 reference

25 December 2017